Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis

Bryan A. Killinger^a, Gabriela Mercado^b, Solji Choi^a, Yaping Chu^c, Patrik Brundin^b, and Jeffrey H. Kordower^c

^a Graduate College, Rush University Medical Center, Chicago Illinois 60612

^b Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids MI 49503

^c ASU-Banner Neurodegenerative Disease Research Center (NDRC), Arizona State University, Tempe Arizona 85287

Synucleinopathies including Parkinson's disease and dementia with Lewy bodies are neurodegenerative diseases characterized by the intracellular accumulation of the protein alpha-synuclein called "Lewy pathology." Alpha-synuclein within Lewy pathology is aggregated into protease resistant filamentous structures and is predominantly phosphorylated at serine 129 (PSER129). Lewy pathology has been hypothesized to spread throughout the nervous system as the disease progresses. Cross-sectional studies have shown the olfactory bulb and olfactory tract consistently bare LP for common synucleinopathies, making these structures likely starting points for the spreading process, and thus disease. Here we examined the distribution of PSER129 in non-diseased brain. To do this we used a sensitive tyramide signal amplification (TSA) technique to detect low abundance endogenous PSER129 under ideal antibody binding conditions. In wild-type non-diseased mice, PSER129 was detected in the olfactory bulb and several brain regions of the olfactory cortex across the neuroaxis (i.e., olfactory bulb to brain stem). PSER129 was particularly apparent in the mitral cell layer and the outer plexiform layer of the olfactory bulb where it was observed as cytosolic/nuclear puncta or fibers, respectively. PSER129 immunoreactivity in the healthy olfactory bulb was abolished by pretreatment of the tissue with proteinase K, pre-absorption of the primary antibody against the purified PSER129 peptide fragment, or the omission of the PSER129 antibody. Furthermore, PSER129 immunoreactivity was not observed in any brain region of alpha-synuclein knockout mice. Dual labeling for the PSER129 and the mitral cell marker TBX21 showed that PSER129 positive structures of the healthy OB were found in mitral cells. We found evidence of the same PSER129 positive structures in the olfactory bulb of non-diseased rats, non-human primates, healthy humans, but not individuals diagnosed with PD. Results suggest biological pathways responsible for alpha-synuclein phosphorylation are constitutively active in OB mitral cells and alpha-synuclein in these cells may be predisposed to pathological aggregation. Pathological seeds originating in mitral cells may act as a source for alpha-synuclein spread competent assemblies that spreads throughout the brain via fibers of the olfactory tract. Future studies should investigate the normal function of alpha-synuclein in the mitral cells of the olfactory bulb, which may give insight into synucleinopathy disease origins.

Introduction

Synucleinopathies are a group of neurodegenerative diseases characterized by intracellular aggregates of alpha-synuclein called "Lewy pathology" (LP). LP are often observed in several characteristic distribution patterns in the diseased brain, which has led to the development of pathology staging schemes^{1,2}. The brain structure that LP is most consistently found in is the OB, where LP is often detected in both the diseased and occasionally in the non-diseased brain (i.e., incidental LP)²⁻⁴. It remains unclear why the OB commonly bares pathology in the human brain, but one possibility is this structure may be prone to pathology development, especially during normal aging⁵. Anosmia is a common prodromal symptom of PD/DLB⁶⁻⁹ strongly supporting the hypothesis that the neurodegenerative process begins in the olfactory bulb years prior to classical symptoms.

LP are complex molecularly heterogeneous intracellular structures containing protease resistant filaments made of misfolded alpha-synuclein predominantly phosphorylated at serine 129 (PSER129). Although alpha-synuclein is predominantly phosphorylated in LP, less than 4% of the total endogenous alpha-synuclein pool is phosphorylated¹⁰. The enrichment of PSER129 for LP strongly suggests this post-translation modification (PTM) plays a role in the disease process, but this exact role remains unclear. Very little is understood about the cellular processes

involved in PSER129 generation and the biological function of PSER129 in the brain. Investigations have primarily focused on whether PSER129 promotes or inhibits alpha-synuclein accumulation as targeting the responsible kinases and/or phosphatases may be a viable therapeutic strategy. To date, PSER129 remains an agnostic proxy for the synucleinopathy disease process. The development of sensitive and specific antibodies to PSER129 has made the detection of LP routine, however the detection of endogenous PSER129 has been inconsistent possibly due to low levels of PSER129 making detection ambiguous and inconsistent¹¹. For example previous attempts to identify endogenous PSER129 by immunohistochemistry have been impeded by high affinity off-target binding of commercially available antibodies that interferes with detection¹¹.

Here we report and expand on an observation we made of PSER129 immunoreactivity in the olfactory bulb (OB) of healthy mammals. To do this we measured PSER129 across the neuroaxis of adult (>150 DPN) wild-type and alpha-synuclein knockout mice using a sensitive tyramide signal amplification (TSA) procedure. We found PSER129 reactivity to be brain region specific with particularly high abundance in the mitral cell layer of the OB. The mitral cell layer of the olfactory bulb contained abundant PSER129 located in perinuclear punctate structures, also in the nuclear compartment, and in fibers projecting out the glomerulus were also heavily labeled. We confirmed these findings in

Distribution of Phosphorylated Alpha-synuclein

the OB of non-synucleinopathy mice, rats, non-human primates, and in the human OB. In contrast, the OB of individuals with PD showed abundant PK resistant PSER129 positive inclusions (i.e., LP) but lacked the PK-sensitive PSER129 mitral cell immunoreactivity observed in the healthy OB. We conclude that alpha-synucleins in OB mitral cells might be predisposed to pathological aggregation.

Results

PSER129 Immunoreactivity in the Mouse Brain

PSER129 staining was regionally specific across the WT mouse brain (Figure 1A). PSER129 staining was most apparent in the olfactory bulb but also several other regions showed pronounced PSER129 staining including the accessory olfactory bulb, amygdala, nucleus accumbens, dentate gyrus, globus pallidus, hypothalamus, and substantia nigra reticulata (Figure 1B). Throughout the tissues PSER129 positive punctate structures could be seen in most

Figure 1: Distribution of PSER129 in the brain of non-diseased mice. (A) Representative images of coronal mouse brain sections stained for PSER129 using tyramide signal amplification. (B) Representative images of select brain regions with apparent PSER129 immunoreactivity at high magnification. Tissues digested with proteinase K (PK), incubated with anti-PSER129 antibody preabsorbed against PSER129 (PA), processed without primary antibody (-Primary) and from mice lacking alpha-synuclein (*Snca*^{-/-}). Representative images of select brain regions are shown. Scale bars = 50 microns. WT mice, n = 14, *Snca*^{-/-} mice, n = 7. (C) Enlarged image from figure B, annotated to show the distribution of PSER129 across layers of the OB.

regions, except for the cerebellum. The brain stem and cerebellum lacked any discernable staining with the notable exception of a group of weakly PSER129 positive cells in the dorsal motor nucleus (not shown). Apparent nuclear staining was observed in many cortical regions including the amygdala. Intense fibers staining was observed in the nucleus accumbens, dentate gyrus, entorhinal cortex, global

pallidus, and substantia nigra pars compacta (Figure 1B). PK digestion prior to immunostaining abolished PSER129 staining across the neuroaxis (Figure 1B, "PK"). Staining was weak when the primary antibody was pre-absorbed against the PSER129 peptide (Figure 1B, "PA"), which is consistent with competitive binding of pre-absorbed monoclonal antibodies (Figure S1,F,G)¹². Staining was totally absent when the primary antibody was omitted from the staining protocol (Figure 1B "-Primary"). PSER129 reactivity appeared variable with some brains showing more prominent staining than others. In total we observed positive PSER129 staining in the OB of 13 out of 14 WT mice tested. In contrast, we did not observe PSER129 reactivity for the 7 alpha-synuclein knockout mice tested in any brain region under any IHC conditions (Figure 1B, *Snca*^{-/-}).

In the olfactory bulb of WT mice, fibers and punctate structures were intensely labeled in the mitral cell layer, while fiber labeling was observed in the external plexiform layer (EPL) and glomeruli (GM) (See figure 1C for annotated reference). Intense labeling of apparent cells and fibers were observed in the accessory olfactory bulb (AOB). PSER129 labeling was nearly absent in the granular layer (GL), inner plexiform layer (IPL), and the olfactory nerve layer (ONL).

PSER129 Occurs as Punctate Structures in Mitral Cells

We wanted to determine the intracellular distribution of PSER129 in the olfactory bulb mitral layer. To do this we

Figure 2: Localization and intracellular distribution of PSER129 in the non-diseased olfactory bulb. (A) PSER129 was fluorescently labeled using tyramide signal amplification in WT mice. Tissues were counterstained with DAPI. Representative images showing distribution of PSER129 in the OB. (B) Non-pathology bearing M83 mice labeled for PSER129. Non-human primate OB was dual labeled for PSER129 and mitral cell marker TBX21. (C) Low magnification confocal images showing regional distribution in non-human primate OB. (D) High magnification confocal images showing PSER129 puncta in TBX21 positive mitral cell. Green arrows denote intracellular punctate structures, both perinuclear and nuclear. WT mice n=5, M83 mice n=2, non-human primates = 2, Scale bars for A and D = 5 microns.

Distribution of Phosphorylated Alpha-synuclein

fluorescently labeled PSER129 in the OB of WT and M83 mice. Results confirmed PSER129 labeling in the mitral cell layer and diffuse punctate labeling in the outer plexiform layer of WT mice. Punctate labeling was observed throughout the plexiform layer. Cells within the mitral layer showed PSER129 granular staining in the nucleus and perinuclear compartments. Punctate PSER129 structures were observed both perinuclear and within the nucleus (Figure 2A and B, green arrows). PSER129 and DAPI weakly colocalized in these cells. M83 mice showed more prominent PSER129 labeling of the mitral cell layer and strong fibers labeling in the plexiform layer. Within the mitral layer cells showed strong nuclear and perinuclear PSER129 labeling. Some punctate structures could be observed in the nucleus and perinuclear, however, they were less pronounced than WT. Punctate PSER129 labeling in the outer plexiform layer extended to the glomerulus. PSER129 staining was not detected in the granular layer of any WT mice tested.

To determine if the punctate PSER129 staining originated in mitral cells we fluorescently labeled both PSER129 and the mitral cell marker TBX21 using the TSA protocol. This experiment was performed in the OB from

healthy non-human primates because the anti-TBX21 antibody used is of mouse origin, and therefore performing this experiment on mouse tissues using our IHC protocol produces ambiguous results. We had already observed the same PSER129 staining pattern in the non-human primate OB (see Figure 3) and therefore chose to assess PSER129 colocalization in this tissue. Results show TBX21 labeling was predominantly nuclear, in select cells of the mitral layer (Figure 2C). TBX21 labeling was observed in some perinuclear structures. Perinuclear PSER129 puncta were observed in TBX21 positive mitral cells. Within mitral cells PSER129 and TBX21 were not colocalize (Figure 2D).

Mitral Cell PSER129 is Conserved Across Species

Next, we wanted to determine if the same PSER129 positive mitral cells were conserved across species. To do this we stained for PSER129 in the olfactory healthy rats, non-human primates (2 years of age), healthy adults, and individuals diagnosed with PD (See Table S1 for Summary). Result showed mitral cell staining in rats, non-human primates, and humans, similar to what was observed in mice (Figure 3A). Antibody clone psyn#64 also detected PSER129 in mitral cells (Figure S2). In the OB of human PD, we found that HIAR or PK digestion were required for PSER129 detection, but in the healthy OB HIAR was often required to observe PSER129 staining (Figure S3). PSER129 staining of the PD OB produces mostly fibers bearing pathology, with a few cell bodies being immunoreactive. PSER129 positive inclusions could be detected across all layers of the OB, however, staining in all cases tested was most prominent in the olfactory tract projecting out through the olfactory peduncle (Figure 3B). We attempted to verify that OB mitral cells were intact in all samples tested using the TBX21 antibody (Figure S4), however, we found immunoreactivity was absent from several human samples (See table S1) which has been reported previously¹³ and may result from differences in post-mortem interval.

Discussion

Mitral cells in synucleinopathies

The OB been hypothesized to be a starting point for alpha-synuclein pathology and therefore the synucleinopathy disease process. This contention is supported by several observations including 1) mitral cell loss in PD OB^{2,5,13,14}, 2) high-incidence of mitral cell LP in synucleinopathy OB^{3,5,15,16} 3) and incidental LP in OB³. Our inadvertent observation of disease associated PSER129 in healthy mitral cells seems to support this hypothesis. However, it is unlikely that all mammalian mitral cells harbor disease causing aggregates, but instead the phosphorylation of alpha-synuclein likely has some unknown biological significance in mitral cells. Currently we can only speculate as to what biological process is responsible for PSER129 in mitral cells. However, because mitral cells eventually develop LP in the disease brain, it is important to understand the biological process generating PSER129 in mitral cells, and if those processes are involved with the alpha-synuclein aggregation process, and thus disease pathogenesis. Factor such as normal aging are likely to have particular significance for mitral cell pathology⁵.

Mitral and tufted cells are primarily glutamatergic neurons of the olfactory bulb, and these cells both seem susceptible to the synucleinopathy disease process while dopaminergic cells of the OB seem resistant¹⁵. Alpha-synuclein oligomers can induce calcium dependent

Figure 3: Mitral cell PSER129 is conserved across species (A) Representative images of PSER129 staining in OB sections from mice, rat, non-human primate, and human. All sections were coronal, except for human OB which was sectioned in the transverse plane. Depicted below each olfactory bulb are high magnification images of staining in the mitral layer. Scale bar = 50 microns. **(B)** Representative images of PSER129 staining in PD/DLB OB. Sections from the main bulb are depicted as well as the peduncle. High magnification images show PSER129 staining in the mitral layer and anterior olfactory nucleus. Scale bar = 50 microns.

glutamate release from astrocytes¹⁷ and can activate extrasynaptic NMDA receptors (eNMDAR) resulting in cytotoxicity¹⁷. NMDA receptors are expressed in mitral cells

Distribution of Phosphorylated Alpha-synuclein

and participate in normal mitral cell function/activity^{18,19}. Mitral cell glutamate release is calcium dependent and self-excitatory via NMDAR's. There is some evidence that glutamate stimulation can increase polo-like kinase 2 expression and PSER129 abundance²⁰. Together, alpha-synuclein's involvement mitral cell glutamate signalling may be related to the observed PSER129 abundance. PSER129 immunoreactivity was most pronounced in mice and monkeys that had been anesthetized with Ketamine (an NMDAR antagonist) prior to perfusion fixation, and less pronounced in rats and humans, who were not exposed to ketamine prior to death. Therefore, it is possible that ketamines effect on glutamate signalling results in PSER129 production in mitral cells. However, one WT mouse exposed to ketamine showed very little PSER129 immunoreactivity in the OB.

Mitral and tufted cells have a apical dendrite that extends to a single glomerular but they also extend several axons into telencephalon regions including the amygdala²¹. These axons extend out through the olfactory tract. We observed occasional LP in the mitral cell layer of DLB and PD OB, but consistently saw dense lewy neurites (LN) throughout the anterior olfactory nuclei of the main bulb and peduncle. Brain regions known to be susceptible to LP were PSER129 immunoreactive in WT mice. If PSER129 containing brain regions are normally susceptible to pathology formation²², then our observations corroborates a hypothesis that olfactory cortex projections are the primary pathogenic origin of synucleinopathies^{14,15,23-26}.

Studies herein were initiated because we had observed regionally specific anomalous PSER129 signal in untreated healthy wildtype mice. Interestingly others have observed this mitral cell staining phenomenon but not realized the significance²⁷. We demonstrated that the anomalous PSER129 signal was likely an endogenous PSER129 population sensitive to PK digestion that occurred in the mitral cells of healthy mammals. In mitral cells both diffuse and punctate structures were intensely labeled in the nucleus, cytoplasm, and often observed throughout their apical dendrite. The apparent pattern of PSER129 staining was seen in mice, rats, non-human primates, and a neurologically intact human. This suggest the role of PSER129 in OB mitral cells is conserved across mammalian species. However, mitral cell PSER129 reactivity was not universal, as we did not observe any staining in 1 mouse and 3 healthy humans. This suggests that either PSER129 is generated in mitral cells driven by undetermined fluctuating cellular process or the PSER129 epitope is not accessible in some tissues. We explore many epitope retrieval methods, and found that heat mediate epitope retrieval could enhance reactivity, but did not unmask reactivity in samples that showed no PSER129 reactivity. In mice, we observed an "all-or-none" phenomenon where samples with little/no OB staining also had little/no staining in other brain regions. The reason for this phenomenon is still not clear.

In agreement with previous reports, results from our studies show that improper dilution of EP1536Y results in abundant off target binding as determined by IHC and blotting techniques (Figure S1,B). In contrast to previous reports, we demonstrate that endogenous PSER129 is

detectable provided EP1536Y is highly dilute and the secondary detection system is sufficiently sensitive (in this case TSA). In our hands we found much higher dilutions of EP1536Y than commonly used (Abcam) are necessary to ensure on target binding, and commonly employed dilutions have a high probability of generating false positive detection. In our hands, EP1536Y could be diluted to ~3 pg / mL (1:1X 0⁹ dilution) and still show on target staining. This gives a large window of effective concentrations for this antibody, as we also observed that non-specific binding is eliminated somewhere between 1:10K and 1:20K dilutions (Fig S1, B).

Synucleinopathy has not been observed as a function of aging in mammals besides humans for unknown reasons. Lesions resembling human tau tangles and amyloid plaques have been observed in mammals other than humans²⁸ but its not clear why LP is not seen in other mammals. The human OB is unique amongst mammals in several aspects including that it only has limited post-natal neurogenesis²⁸. Human samples had the least prominent PSER129 staining of all species tested (Figure 3A). One possibility is that PSER129 represents a protective mechanism that prevents pathological aggregation²⁹ and perhaps human mitral cells are particularly deficient in this neuroprotective phosphorylation event as they age.

Study Limitations

Studies herein are based on antibody affinity, and although we have included several controls (i.e., alpha-synuclein knockout mice, antibody preabsorption, and primary antibody negative conditions) we cannot rule out the possibility of immune mimicry¹². However, our finding that under several IHC protocols tested (e.g., HIAR, PK), we did not observe any PSER129 immunoreactivity in any brain structure of seven alpha-synuclein knockout mice. In contrast, nearly all (14/15) of the WT mice tested had readily apparent immunoreactivity in the OB mitral layer.

Conclusion

OB mitral cells harbor the disease associated alpha-synuclein PTM PSER129 and have previously implicated in disease pathogenesis. We conclude that determining the cellular and molecular processes that regulate PSER129 in OB mitral cells might provide important insights into the origins of synucleinopathies.

References

- 1 Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24, 197-211, doi:10.1016/s0197-4580(02)00065-9 (2003).
- 2 Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. *Acta Neuropathol* 117, 613-634, doi:10.1007/s00401-009-0538-8 (2009).
- 3 Beach, T. G. et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. *Acta Neuropathol* 119, 689-702, doi:10.1007/s00401-010-0664-3 (2010).
- 4 Beach, T. G. et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. *Acta Neuropathol* 117, 169-174, doi:10.1007/s00401-008-0450-7 (2009).
- 5 Sengoku, R. et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. *J Neuropathol Exp Neurol* 67, 1072-1083, doi:10.1097/NEN.0b013e31818b4126 (2008).
- 6 Olichney, J. M. et al. Anosmia is very common in the Lewy body variant of Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 76, 1342-1347, doi:10.1136/jnnp.2003.032003 (2005).

Distribution of Phosphorylated Alpha-synuclein

- 7 Ross, G. W. et al. Association of olfactory dysfunction with risk for future Parkinson's disease. *Ann Neurol* 63, 167-173, doi:10.1002/ana.21291 (2008).
- 8 Chiba, Y. et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer's disease. *Dement Geriatr Cogn Disord* 33, 273-281, doi:10.1159/000339363 (2012).
- 9 Fujishiro, H. et al. Dementia with Lewy bodies: early diagnostic challenges. *Psychogeriatrics* 13, 128-138, doi:10.1111/psyg.12005 (2013).
- 10 Fujiwara, H. et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4, 160-164, doi:10.1038/ncb748 (2002).
- 11 Delic, V. et al. Sensitivity and specificity of phospho-Ser129 alpha-synuclein monoclonal antibodies. *J Comp Neurol* 526, 1978-1990, doi:10.1002/cne.24468 (2018).
- 12 Ivell, R., Teerds, K. & Hoffman, G. E. Proper application of antibodies for immunohistochemical detection: antibody crimes and how to prevent them. *Endocrinology* 155, 676-687, doi:10.1210/en.2013-1971 (2014).
- 13 Cave, J. W., Fujiwara, N., Weibman, A. R. & Baker, H. Cytoarchitectural changes in the olfactory bulb of Parkinson's disease patients. *NPJ Parkinsons Dis* 2, 16011, doi:10.1038/npjparkd.2016.11 (2016).
- 14 Daniel, S. E. & Hawkes, C. H. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. *Lancet* 340, 186, doi:10.1016/0140-6736(92)93275-r (1992).
- 15 Ubeda-Banon, I. et al. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells. *Acta Neuropathol* 119, 723-735, doi:10.1007/s00401-010-0687-9 (2010).
- 16 Kovacs, T., Papp, M. I., Cairns, N. J., Khan, M. N. & Lantos, P. L. Olfactory bulb in multiple system atrophy. *Mov Disord* 18, 938-942, doi:10.1002/mds.10466 (2003).
- 17 Trudler, D. et al. alpha-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss. *J Neurosci* 41, 2264-2273, doi:10.1523/JNEUROSCI.1871-20.2020 (2021).
- 18 Philipot, B. D., Lyders, E. M. & Brunjes, P. C. The NMDA receptor participates in respiration-related mitral cell synchrony. *Exp Brain Res* 118, 205-209, doi:10.1007/s002210050273 (1998).
- 19 Ennis, M., Zimmer, L. A. & Shipley, M. T. Olfactory nerve stimulation activates rat mitral cells via NMDA and non-NMDA receptors in vitro. *Neuroreport* 7, 989-992, doi:10.1097/00001756-199604100-00007 (1996).
- 20 Tan, Y. et al. LY354740 Reduces Extracellular Glutamate Concentration, Inhibits Phosphorylation of Fyn/NMDARs, and Expression of PLK2/pS129 alpha-Synuclein in Mice Treated With Acute or Sub-Acute MPTP. *Front Pharmacol* 11, 183, doi:10.3389/fphar.2020.00183 (2020).
- 21 Scott, J. W., McBride, R. L. & Schneider, S. P. The organization of projections from the olfactory bulb to the piriform cortex and olfactory tubercle in the rat. *J Comp Neurol* 194, 519-534, doi:10.1002/cne.901940304 (1980).
- 22 Zhou, J. et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. *Acta Neuropathol* 121, 695-704, doi:10.1007/s00401-011-0815-1 (2011).
- 23 Del Tredici, K., Rub, U., De Vos, R. A., Bohl, J. R. & Braak, H. Where does parkinson disease pathology begin in the brain? *J Neuropathol Exp Neurol* 61, 413-426, doi:10.1093/jnen/61.5.413 (2002).
- 24 Hoogland, P. V., van den Berg, R. & Huisman, E. Misrouted olfactory fibres and ectopic olfactory glomeruli in normal humans and in Parkinson and Alzheimer patients. *Neuropathol Appl Neurobiol* 29, 303-311, doi:10.1046/j.1365-2990.2003.00459.x (2003).
- 25 Hubbard, P. S., Esiri, M. M., Reading, M., McShane, R. & Nagy, Z. Alpha-synuclein pathology in the olfactory pathways of dementia patients. *J Anat* 211, 117-124, doi:10.1111/j.1469-7580.2007.00748.x (2007).
- 26 Ubeda-Banon, I., Flores-Cuadrado, A., Saiz-Sanchez, D. & Martinez-Marcos, A. Differential Effects of Parkinson's Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus. *Front Neuroanat* 11, 113, doi:10.3389/fnana.2017.00113 (2017).
- 27 Niu, H. et al. IL-1beta/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-Synuclein pathology in the olfactory bulb, substantia nigra and striatum. *Brain Pathol* 30, 1102-1118, doi:10.1111/bpa.12886 (2020).
- 28 Arnsten, A. F. T. et al. Alzheimer's-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of

Alzheimer's disease. *Proc Natl Acad Sci U S A*, doi:10.1073/pnas.1903671116 (2019).

- 29 Arawaka, S., Sato, H., Sasaki, A., Koyama, S. & Kato, T. Mechanisms underlying extensive Ser129-phosphorylation in alpha-synuclein aggregates. *Acta Neuropathol Commun* 5, 48, doi:10.1186/s40478-017-0452-6 (2017).

Acknowledgements

Human brain samples were generously provided by several tissue banks including the Rush Movement Disorders Brain Bank, the Alzheimer's Brain Bank, and BH Banner Health Research. Funding for this work was provided by NIDCD Award #R01DC06519 (PB and GM) and NINDS Award #5R21NS109871-02 (JHK).

Competing interest statement

We have no competing interests to declare.

Materials and Methods

Biological Specimens

All rodent and non-human primate tissues were derived from studies conducted in accordance with institutional IACUC approved protocols. All animals were anesthetized (ketamine/xylazine for rodents, and ketamine/xylazine/hydromorphone for non-human primates) transcranially perfused with PBS pH 7.4 followed by 4% paraformaldehyde in PBS pH 7.4. Collected brain tissues were then post fixed in 4% paraformaldehyde overnight at 4°C, dehydrated in successive sucrose solutions in PBS (i.e., 10%, 20%, and 30% sucrose, w/v), and cut to 40-micron coronal sections on a freezing stage microtome. Human olfactory bulbs from individual diagnosed with PD were supplied by the Rush Movement Disorders Brain Bank. OB specimens from individuals without synucleinopathy (HC) were provided by Rush Alzheimer's Brain Bank and BH Banner Health Research. Human and non-human primate OBs were sectioned following embedding in OCT compound (ThermoFisher). One human non-synucleinopathy case was obtained from banner health embedded in paraffin wax.

Immunohistochemistry

Free floating paraformaldehyde fixed mouse sections gathered at intervals of 940 microns across the neuroaxis (i.e. OB to brainstem) were first incubated in peroxidase quenching solution (0.3% hydrogen peroxide, 0.1% sodium azide) in TBST (50 mM Tris-HCl pH 7.6, 150mM NaCl, and 0.5% Triton X-100) for 30 min at room temperature. Sections were then rinsed twice with PBS, and incubated with blocking buffer (3% goat serum, 2% BSA, TBST) for 1 h at room temperature. Sections were then incubated with either anti-PSER129 (Abcam) diluted 1:50,000 or TBX21 antibody (SantaCruz) diluted 1:10,000 in blocking buffer overnight at 4°C. The next day sections were washed twice with TBST and incubated with biotinylated anti-rabbit or anti-mouse antibodies (Vectorlabs) diluted 1:400 in blocking buffer for 1h at room temperature. Sections were then wash 3 times for ten minutes each in TBST and then incubated with prepared elite ABC reagent (Vector Labs) for 1h at room temperature. Sections were then washed 2 times for 10 min in TBST and then washed 2 times for 10 min in sodium borate buffer (0.05M Sodium Borate, pH 8.5). Sections were then incubated 30 min with amplification buffer consisting of 1 µg / mL biotinyl tyramide (ThermoFisher) and 0.003% hydrogen peroxide diluted in sodium borate buffer. Then sections were washed 3 times for 10 min in TBST and incubated again in the previously prepared elite ABC reagent for 1 h at room temperature. Sections were then washed 3 times for 10 min in TBST. Sections were then developed for exactly 2 min using a standard nickel enhanced DAB-imidazole protocol. Mounted sections were counterstained with methylgreen, dehydrated with ethanol, cleared with xylenes, and coverslipped with cytooseal 60.

For some experiments sections were digested with proteinase K prior to IHC. These sections were first mounted onto gelatin coated slides, dried, and baked overnight at 55°C. Slides were then placed into PBS for 10 min and then proteinase K digestion buffer (TBS, 0.1% triton X100, 20µg proteinase K/mL, warmed to 37°C) for 20 min. Sections were rinsed with PBS, incubated with 4% paraformaldehyde for 10 min, and rinsed off twice with TBST. Digested sections were then processed as stated above. For some experiments heat induced antigen retrieval (HIAR) was performed prior to staining. To perform HIAR citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6.0) was heated in a water bath to 95°C, slides then immersed in this solution for 30 min, and then allowed to cool to room temperature.

For fluorescent detection, CF-546 or CF-647 tyramide conjugates (Biotium) were substituted for biotinyl tyramide at a final

Distribution of Phosphorylated Alpha-synuclein

concentration of 1 µg / mL. Incubation with fluorescent tyramides was restricted to 20 min to avoid saturated fluorescent labeling. Fluorescently labeled sections were mounted onto gelatin coated slides, dried for 20 min, and mounted with #1 glass coverslip using FluoroShield (Sigma-Aldrich).

For some experiments paraffin embedded sections were used. Prior to IHC these sections were heated in an oven to 60°C, cleared with xylenes, and rehydrated with successive ethanol solutions from 100% to 50%. Once hydrated sections were processed according to immunostaining protocols.

Microscopy

All samples were imaged on an inverted confocal microscope (Nikon A1R). Whole slide bright-field images using a 4X or 10X objective were acquired for DAB labeled sections. Confocal images were acquired for fluorescently labeled sections using a 60X oil immersion objective. Confocal images were deconvoluted using Nikon elements software.

Distribution of Phosphorylated Alpha-synuclein

Table S1: List of Specimens and Summary of Results.

#	Species	Sex	Age at death (yrs)	Method of fixation	Strain	Genotype	EP1536Y staining*	TBX21 staining†	Disease
1	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
2	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
3	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
4	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
5	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	WT	1	1	NA
6	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	WT	1	1	NA
7	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	WT	0	1	NA
8	<i>Mus musculus</i>	M	0.66	PF/DF	C57BL/6J	WT	1	1	NA
9	<i>Mus musculus</i>	M	0.83	PF/DF	C57BL/6J	WT	1	ND	NA
10	<i>Mus musculus</i>	M	0.83	PF/DF	C57BL/6J	WT	1	ND	NA
11	<i>Mus musculus</i>	M	0.83	PF/DF	C57BL/6J	WT	1	ND	NA
12	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
13	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
14	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	α -syn KO	0	1	NA
15	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	WT	1	1	NA
16	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	WT	1	1	NA
17	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	WT	1	1	NA
18	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	WT	1	1	NA
19	<i>Mus musculus</i>	F	0.66	PF/DF	C57BL/6J	WT	1	1	NA

Distribution of Phosphorylated Alpha-synuclein

20	<i>Mus musculus</i>	F	0.83	PF/DF	C57BL/6J	WT	1	ND	NA
21	<i>Mus musculus</i>	F	0.83	PF/DF	C57BL/6J	WT	1	ND	NA
22	<i>Rattus norvegicus domestica</i>	NA	1.33	DF	SD	WT	0	1	NA
23	<i>Rattus norvegicus domestica</i>	NA	1.33	DF	SD	WT	1	1	NA
24	<i>Rattus norvegicus domestica</i>	NA	1.33	DF	SD	WT	1	1	NA
‡25	<i>Macaca fascicularis</i>	M	10.86	PF/DF	NA	WT	1	1	NA
26	<i>Macaca fascicularis</i>	F	5.59	PF/DF	NA	WT	1	1	NA
27	<i>Homo sapiens</i>	M	93.24	DF	NA	NA	0	0	NS
28	<i>Homo sapiens</i>	M	87.8	DF	NA	NA	0	ND	NS
29	<i>Homo sapiens</i>	F	74.1	DF	NA	NA	0	0	NS
30	<i>Homo sapiens</i>	F	87	DF-Paraffin	NA	NA	1	1	NS
31	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	0	0	PD/DLB
32	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	0	0	PD/DLB
33	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	0	0	PD/DLB
34	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	0	0	PD/DLB
35	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	0	0	PD/DLB
§36	<i>Homo sapiens</i>	NK	NK	DF	NA	NA	1	1	PD/DLB

Notes. * EP1536Y was used to stain mitral cell PSER129. †TBX21 is a mitral cell marker. 0 means no staining and 1 means staining. ‡For specimen 25, animal was euthanized due to post op-right subdural hematoma. §Specimen 36 had weak TBX-21 staining but was observed in the citrate retrieval condition. DF = Drop-fixation, PF=Perfusion fixation, DF-Paraffin = Drop-fixation followed by paraffin embedding. NS = non-synucleinopathy. PD/DLB = Clinical Parkinson's disease or Dementia with Lewy bodies, postmortem conformation by pathology. NK = not known.

Distribution of Phosphorylated Alpha-synuclein

Figure S1: Validation Experiments in M83 mice and WT mice. (A) Dot-blot demonstrates EP1536Y reactivity against several samples of interest. **(B)** EP1536Y dilution experiments. Brain sections from wild-type mice were probed with the antibody BDSYN1 (total synuclein) or several dilutions of EP1536Y and developed with DAB or nickel enhanced DAB. Low and high magnification images of the resulting reactivity. Higher dilutions were required to avoid perfuse reactivity in the brain. **(D)** PSER129 reactivity in WT and A53T alpha-synuclein over-expressing mice (M83). At high dilutions, PSER129 reactivity was seen throughout the M83 brain. **(E)** Antibody MJFR1 only reacts to human alpha-synuclein. M83 mice show similar tissue distribution of human alpha-synuclein as PSER129 tissues distribution. This suggests that expressed human alpha-synuclein is phosphorylated. **(F)** Preabsorption of EP1536Y antibody. The antibody was preabsorbed against excesses alpha-synuclein phosphopeptide (abcam). The preabsorbed antibody was then used to stain brain sections from M83 mice not bearing alpha-synuclein pathology. Results show a reduction in signal, but not a loss of staining, typical of monoclonal antibody reactivity. **(G)** Preabsorbed antibody was used to stain proteinase K treated M83 mouse brains bearing alpha-synuclein pathology. Similarly, pathology detection was inhibited with preabsorption, but not eliminated.

Non-human Primate

Figure S2: Antibody pSyn#64 reactivity in OB of a healthy non-human primate. Formalin fixed floating coronal sections from a cynomolgus monkey were incubated with mouse monoclonal antibody pSyn#64 (FuJIFILM Wako Pure Chemical Corporation) and detected using tyramine signal amplification. Sections were counterstained with methyl green. The left image depicts a whole section scan, and the left image depicts an image taken with a 20X objective. Scale bars are depicted on each image.

Distribution of Phosphorylated Alpha-synuclein

Figure S3: Detection of PSER129 is dependent on antigen retrieval techniques. Olfactory bulb sections from a non-human primate (A) and individual with PD (B) were immunostained using the EP1536Y antibody under different tissue processing conditions. For the “no treatment” condition tissues were stained as floating sections without antigen retrieval. For “HIAR” tissues were mounted onto slides and heated to ~95°C in citrate buffer for 30 min. For “PK” samples were mounted onto slides and treated with 20 µg/mL proteinase K for 10 min at 37°C. Resulting EP1536Y immunoreactivity for each condition is depicted. Red arrow highlights PSER129 reactivity in mitral cells.

Distribution of Phosphorylated Alpha-synuclein

Figure S4: TBX21 reactivity in the OB. Immunoreactivity of mitral cell marker TBX21 in OB specimens from each species assessed in this study. TBX21 reactivity was observed in the mitral cell layer across species. High background was observed in the mouse specimens because the anti-TBX21 antibody was of mouse origin.